Tag: Drug development

Over 90% of drug candidates that enter the clinical trial stage fail to reach the market, highlighting the immense difficulty in getting FDA approval. This staggering statistic underscores the complex and high-risk nature of pharmaceutical research and development, a process fraught with challenges at every turn.

Over 10 million people worldwide are living with Parkinson's disease, a progressive neurological disorder. Managing symptoms has seen significant advancement with the question, **what is the new drug for Parkinson's disease?**, leading to recent FDA approvals for more advanced treatment options, including new infusion pumps and extended-release medications.

In a significant development for the rare disease community, the FDA approved the first-ever treatment for Friedreich's ataxia in early 2023, offering a major breakthrough after years with no disease-specific drugs. This milestone, along with other promising therapies currently under review, provides a clearer answer to the question, "What is the new medicine for ataxia?" and fuels optimism for future treatments across various forms of this debilitating condition.

Recent analyses show that only about 52% of drugs successfully transition from Phase 1 to Phase 2 clinical trials [1.6.2]. This highlights the critical nature of understanding the question: **what is phase 1 and phase 2 in medical** research and drug development?

The furan ring, a simple five-membered aromatic heterocycle, is a foundational scaffold for a surprising number of essential medicines [1.3.2]. The question of *What drugs are made from furan?* reveals a diverse list spanning from diuretics to antibiotics and antiarrhythmics [1.2.3, 1.3.1].

Riluzole was the first drug approved by the FDA for the treatment of Amyotrophic Lateral Sclerosis (ALS) in 1995. However, a newer medication, troriluzole, was developed as an optimized prodrug of riluzole, aiming to improve its pharmacokinetic properties and side effect profile.

In pharmacology, the half-maximal inhibitory concentration (IC50) is a critical measure for assessing a drug's potency, representing the concentration required to inhibit a biological process by 50%. This value is fundamental to drug discovery and understanding inhibitory effectiveness. So, is high or low IC50 better for a medication?

An estimated 90% of drug candidates that enter clinical trials ultimately fail [1.8.2]. To improve success rates, researchers rely on key metrics like the half-maximal inhibitory concentration (IC50). So, what is the interpretation of IC50 values, and how does it guide drug discovery?

Scorpion venom is one of the most expensive liquids in the world, with some estimates valuing it at $39 million per gallon [1.3.2, 1.9.4]. The answer to 'What is the drug called scorpion?' is complex; it refers not to a single substance but to a range of compounds, from an FDA-approved antivenom to revolutionary cancer-fighting agents [1.2.3, 1.4.1].

With high rates of drug candidate attrition in clinical development, a thorough understanding of **what is characterization of a drug?** is paramount for ensuring a successful and safe final product. This comprehensive analysis of a drug's properties is a cornerstone of pharmaceutical science, underpinning the entire lifecycle of a medication from discovery to market.